CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. You should consider whether you understand how CFDs work and can afford the risks. Trading CFDs is high risk and is not suitable for everyone. Refer to our PDS and Target Market Determination. AFSL 513393
Open platformOpen platform

Corcept Reports Positive Results From Phase 2 Bella Trial Of Lifyorli® Combined With NAB-Paclitaxel And Bevacizumab In Patients With Platinum-Resistant Ovarian Cancer

By Reuters News

Oct 26 (Reuters) - Corcept Therapeutics Incorporated CORT.O:

  • CORCEPT REPORTS POSITIVE RESULTS FROM PHASE 2 BELLA TRIAL OF LIFYORLI® COMBINED WITH NAB-PACLITAXEL AND BEVACIZUMAB IN PATIENTS WITH PLATINUM-RESISTANT OVARIAN CANCER

  • CORCEPT THERAPEUTICS INCORPORATED - 88% OF PATIENTS ALIVE AT 6-MONTH OS TIMEPOINT IN BELLA TRIAL

  • CORCEPT THERAPEUTICS INCORPORATED - NO NEW SAFETY SIGNALS IDENTIFIED IN BELLA TRIAL FOR LIFYORLI COMBINATION

  • CORCEPT THERAPEUTICS INCORPORATED - MEDIAN PFS OF 7.2 MONTHS FOR LIFYORLI PLUS NAB-PACLITAXEL AND BEVACIZUMAB IN BELLA

Further company coverage: CORT.O

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.